Pfizer Urges FDA To Prohibit Generic Exclusivity Transfer For Gabapentin

Allowing generic drug companies to use "first-to-file" exclusivity as a licensable asset will lead to "speculative" ANDA filings, Pfizer warned in a citizen petition seeking to block approval of Teva's generic version of gabapentin (Neurontin)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet